Download Medical Notes on United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 3 Medical Notes

About This Presentation

Description:United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 is presented in five separate booklets. The report gives an updated overview of recent trends on drug production, drug trafficking and consumption of key illicit drugs. The Report contains a global overview of the baseline data and estimates on drug demand and drug supply. The report also provides the reference point for information on the drug situation worldwide. Booklet 3 of the United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 deals with Depressants.

Tags:pharmaceutical companies,Drug Development, drug supply, drug consumption, illicit drugs, drug demand, Depressants

Published on: Jun 30, 2020 | Views : 1521 | Downloads : 1

Comment

Transcript

No transcript available for this presentation

User Presentation
Related Presentations

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 5

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 5

Managed Care Models: The Benefit vs. Cost Balance

Generics and Biosimilars Industry Response to COVID-19

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Specialty Pharmacy and Biosimilars

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 5

2019 R&D Achievements New product launches, clinical trial activity, and investments

Emerging Biopharma’s Contribution to Innovation

Orphan Drugs in the United States - Exclusivity, Pricing and Treated Populations

Biopharma Companies Join Forces to Fight COVID-19

HEALTH A TO Z